India Generics Makers See U.S. Inspection Fees As Positive Move
This article was originally published in PharmAsia News
Executive Summary
Indian manufacturers of generic drugs expressed comfort with U.S. legislation that would increase the number of U.S. FDA inspections of pharmaceutical facilities abroad, primarily in India and China.